Ischemic optic neuropathy is caused due to a small vessel infraction of the optic nerve and is a major cause of blindness or impaired vision among the inflicted. There are two types of ischemic optic neuropathies viz. anterior ischemic optic neuropathy and posterior or non-anterior ischemic optic neuropathy. Anterior ischemic optic neuropathy is caused by the inflammation of arteries supplying blood to the optic nerve whereas posterior or non-anterior ischemic optic neuropathy is caused due to reasons other than inflammation of the arteries. Anterior ischemic optic neuropathy is more prevalent as compared to posterior ischemic optic neuropathy. In anterior ischemic optic neuropathy, immediate treatment is required to prevent vision loss in the fellow eye as approximately 50 percent of cases have chances of blindness in another eye within a span of 5 to 10 days without treatment. The symptoms of ischemic optic neuropathy include unilateral, acute and painless visual loss for hours to days. Hypertension, diabetes, and hypercholesterolemia are some of the well-known risk factors associated with ischemic optic neuropathy disease. Other factors include generalized hypoperfusion, sleep apnea, nocturnal hypotension, vasospasm, severe anemia and failure of autoregulation.
Technological advancements in ischemic optic neuropathy treatment and availability of alternative drugs are anticipated boost the demand for ischemic optic neuropathy treatments over the forecast period.
The global ischemic optic neuropathy treatment market can be segmented on the basis of disease type, treatment type and end user.
On the basis of disease type, the global ischemic optic neuropathy treatment market can be segmented into:
On the basis of treatment type, the global ischemic optic neuropathy treatment market can be segmented into:
On the basis of end user, the global ischemic optic neuropathy treatment market can be segmented into:
The global ischemic optic neuropathy treatment market is expected to register a significant CAGR over the forecast period. The increasing adoption of recently approved intravitreal implants in the treatment of ophthalmology diseases is anticipated to propel the growth of the ischemic optic neuropathy treatment market over the forecast period. Leading pharmaceutical and drug manufacturing companies from developed countries are substantially investing in R&D, infrastructure and new technologies in ophthalmology therapeutics to capture a market share in the growing burden of eye diseases, which also boosts the growth of the global ischemic optic neuropathy treatment market. With growing awareness towards eye-related complications that lead to blindness, geriatric population and diabetic patients in developed countries, such as the U.S., Russia, and Poland, Germany and Japan are seen to have a proactive approach for treatment related to complications rather than reactive treatment, which also bolsters the growth of the market of ischemic optic neuropathy treatment.
Corticosteroid is the first choice of therapy for patients with ischemic optic neuropathy in prominent countries, such as the U.S., Germany, France, and Russia; however, a majority of patients have developed resistance to anti-VEGF, which leads to the adoption of alternative therapy in patients with ischemic optic neuropathy. This is anticipated to drive the growth of the global ischemic optic neuropathy treatment market in the long run.
However, medications such as intravitreal injections of anti-VEGF drugs and corticosteroids lead to an instant increase in intraocular pressure, which may lead to severe adverse effects such as conjunctival haemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased and vitreous detachment. This may restrain the growth of the global ischemic optic neuropathy treatment market.
On the basis of regional presence, the global ischemic optic neuropathy treatment market can segmented into five key regions, namely North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa.
North America is a dominant region in the market and contributes a leading share to the global ischemic optic neuropathy treatment market in terms of revenue. The market in the region is expected to register significant growth over the forecast period due to the availability of developed medical infrastructure and treatment facilities in the region. Europe also contributes a moderate share and registered a healthy growth rate in the global ischemic optic neuropathy treatment market. The APEJ region has become a lucrative market for ischemic optic neuropathy treatment and is anticipated to register a significant share over the forecast period, due to the increase in research and development activities along with the growth in medical tourism in the region. Latin America and MEA are in the nascent stage in the global ischemic optic neuropathy treatment market and are expected to register moderate growth over the forecast period.
Some of the market players operating in the ischemic optic neuropathy treatment market include Allergan, Plc., Pfizer, Inc., Novartis AG, F. Hoffman - La Roche Ltd., AbbVie Inc., Bayer AG, Valeant Pharmaceuticals Inc., Alimera Sciences Inc. and Amgen, Inc.
The report covers exhaustive analysis on:
Regional analysis includes
Benevolence regarding Advancements in Ophthalmalogy to boost the ischemic optic neuropathy treatment market
Persistence Market Research states that the global ischemic optic neuropathy treatment market will get on to the exponential growth mode between 2020 and 2030.
ischemic optic neuropathy treatment market is driven by rising awareness about the ocular ailments, especially posterior ischemic optic neuropathy and anterior ischemic optic neuropathy. These two ailments are reported to be the major reason of blindness as optic nerve gets infracted. The risk factors auxiliary to ischemic optic neuropathy include hypercholesterolemia, diabetes, and hypertension. The other factors are inclusive of failure on the part of autoregulation, severe anemia, vasospasm, nocturnal hypotension, sleep apnea, and generalized hypoperfusion.
The above-mentioned factors would certainly hold the hopes high for ischemic optic neuropathy treatment market.
The outbreak of Covid-19 has sent across waves of uncertainty almost everywhere. As such, people are refraining from going for ischemic optic neuropathy amidst partial/total lockdown. This situation is expected to continue till mid-2021 (till Covid-19 vaccine is in place).
North America rules the ischemic optic neuropathy treatment market owing to provision of enhanced healthcare infrastructure with growing spending on research in ophthalmology. Europe comes in second on this count. The Asia-Pacific is expected to grow at the fastest pace in the years to come due to rising medical tourism coupled with more medical aspirants turning towards ophthalmology. In other words, the Asia-Pacific could be looked upon as a major revenue generator in ischemic optic neuropathy treatment market going forward.
The key players in the ischemic optic neuropathy treatment market include Novartis AG, Pfizer, Inc., F. Hoffman – La Roche Ltd, AbbVie Inc., Alimera Sciences Inc., and Valeant Pharmaceuticals Inc. On the development front, Pfizer, Inc., in Jul 2019, did acquire Array BioPharma Inc. The objective of acquisition was that of strengthening new-fangled biopharmaceutical business and look into treating ailments like cancer.